The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells

Molecular Immunology

Volumn 47, Issue 14, 2010, Pages 2388-2396

  Feng, Xiaoli ^a,b,c   Yan, Jie ^b   Wang, Yibiao ^c   Zierath, Juleen R ^b   Nordenskjöld, Magnus ^b   Henter, Jan Inge ^b   Fadeel, Bengt ^a   Zheng, Chengyun ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Multiple myeloma; Natural killer cell; Proteasome inhibitor; TRAIL

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; MESSENGER RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION; DOWN REGULATION; EXOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR CELL;

ADULT; APOPTOSIS; BASE SEQUENCE; BORONIC ACIDS; CELL DEGRANULATION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DNA PRIMERS; DOWN-REGULATION; HUMANS; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MULTIPLE MYELOMA; NF-KAPPA B; PROTEASE INHIBITORS; PYRAZINES; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77955415749     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.05.003     Document Type: Article

References (42)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 2004, 4:349-360.
2. Baetu T.M., Kwon H., Sharma S., Grandvaux N., Hiscott J. Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J. Immunol. 2001, 167:3164-3173.
3. Balsas P., Lopez-Royuela N., Galan-Malo P., Anel A., Marzo I., Naval J. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem. Pharmacol. 2009, 77:804-812.
4. Basler M., Lauer C., Beck U., Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J. Immunol. 2009, 183:6145-6150.
5. Berges C., Haberstock H., Fuchs D., Miltz M., Sadeghi M., Opelz G., Daniel V., Naujokat C. Proteasome inhibition suppresses essential immune functions of human CD4(+) T cells. Immunology 2008, 124:234-246.
6. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., Carvajal-Vergara X., Mateos J., Vidriales B., Lopez-Holgado N., Maiso P., Alberca M., Villaron E., Schenkein D., Pandiella A., San Miguel J. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
7. Bryceson Y.T., Rudd E., Zheng C., Edner J., Ma D., Wood S.M., Bechensteen A.G., Boelens J.J., Celkan T., Farah R.A., Hultenby K., Winiarski J., Roche P.A., Nordenskjold M., Henter J.I., Long E.O., Ljunggren H.G. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 2007, 110:1906-1915.
8. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
9. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 2002, 168:1356-1361.
10. Falschlehner C., Schaefer U., Walczak H. Following TRAIL's path in the immune system. Immunology 2009, 127:145-154.
11. Gilmore T.D. Multiple myeloma: lusting for NF-kappaB. Cancer Cell 2007, 12:95-97.
12. Gomez-Benito M., Martinez-Lorenzo M.J., Anel A., Marzo I., Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp. Cell Res. 2007, 313:2378-2388.
13. Hallett W.H., Ames E., Motarjemi M., Barao I., Shanker A., Tamang D.L., Sayers T.J., Hudig D., Murphy W.J. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol. 2008, 180:163-170.
14. Kataoka T., Shinohara N., Takayama H., Takaku K., Kondo S., Yonehara S., Nagai K. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 1996, 156:3678-3686.
15. Kayagaki N., Yamaguchi N., Nakayama M., Takeda K., Akiba H., Tsutsui H., Okamura H., Nakanishi K., Okumura K., Yagita H. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 1999, 163:1906-1913.
16. Labrinidis A., Diamond P., Martin S., Hay S., Liapis V., Zinonos I., Sims N.A., Atkins G.J., Vincent C., Ponomarev V., Findlay D.M., Zannettino A.C., Evdokiou A. Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin. Cancer Res. 2009, 15:1998-2009.
17. Lincz L.F., Yeh T.X., Spencer A. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001, 15:1650-1657.
18. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol. Lett. 2003, 139:89-97.
19. McCloskey S.M., McMullin M.F., Walker B., Irvine A.E. The therapeutic potential of the proteasome in leukaemia. Hematol. Oncol. 2008, 26:73-81.
20. Mitsiades C.S., Treon S.P., Mitsiades N., Shima Y., Richardson P., Schlossman R., Hideshima T., Anderson K.C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001, 98:795-804.
21. Mitsiades N., Mitsiades C.S., Poulaki V., Anderson K.C., Treon S.P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002, 99:2162-2171.
22. Morissette M.C., Vachon-Beaudoin G., Parent J., Chakir J., Milot J. Increased p53 level, Bax/Bcl-x(L) ratio, and TRAIL receptor expression in human emphysema. Am. J. Respir. Crit. Care Med. 2008, 178:240-247.
23. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol. 2008, 9:1157-1165.
24. Phillips J.H., Lanier L.L. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J. Exp. Med. 1986, 164:814-825.
25. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348:2609-2617.
26. Saudemont A., Jouy N., Hetuin D., Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 2005, 105:2428-2435.
27. Screpanti V., Wallin R.P., Ljunggren H.G., Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J. Immunol. 2001, 167:2068-2073.
28. Seki N., Hayakawa Y., Brooks A.D., Wine J., Wiltrout R.H., Yagita H., Tanner J.E., Smyth M.J., Sayers T.J. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 2003, 63:207-213.
29. Shah J.J., Orlowski R.Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009, 23:1964-1979.
30. Smyth M.J., Cretney E., Kelly J.M., Westwood J.A., Street S.E., Yagita H., Takeda K., van Dommelen S.L., Degli-Esposti M.A., Hayakawa Y. Activation of NK cell cytotoxicity. Mol. Immunol. 2005, 42:501-510.
31. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., Yagita H., Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 2001, 193:661-670.
32. Smyth M.J., Takeda K., Hayakawa Y., Peschon J.J., van den Brink M.R., Yagita H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003, 18:1-6.
33. Straube C., Wehner R., Wendisch M., Bornhauser M., Bachmann M., Rieber E.P., Schmitz M. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007, 21:1464-1471.
34. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S., Iwakura Y., Yagita H., Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 2001, 7:94-100.
35. Tobinai K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int. J. Clin. Oncol. 2007, 12:318-326.
36. Togashi K., Kataoka T., Nagai K. Characterization of a series of vacuolar type H(+)-ATPase inhibitors on CTL-mediated cytotoxicity. Immunol. Lett. 1997, 55:139-144.
37. Utecht K.N., Kolesar J. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am. J. Health Syst. Pharm. 2008, 65:1221-1231.
38. Wang X., Ottosson A., Ji C., Feng X., Nordenskjold M., Henter J.I., Fadeel B., Zheng C. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 2009, 94:470-478.
39. Wilson N.S., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 2009, 10:348-355.
40. Yagita H., Takeda K., Hayakawa Y., Smyth M.J., Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004, 95:777-783.
41. Zheng C., Ostad M., Andersson M., Celsing F., Holm G., Sundblad A. Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. Br. J. Haematol. 2002, 118:778-785.
42. Zhou J., Zhang J., Lichtenheld M.G., Meadows G.G. A role for NF-kappa B activation in perforin expression of NK cells upon IL-2 receptor signaling. J. Immunol. 2002, 169:1319-1325.